Search results for " alpha-2"

showing 10 items of 104 documents

Divergent in vivo and in vitro antileukemic activity of recombinant interferon beta in patients with chronic-phase chronic myelogenous leukemia

1993

It was the aim of this study to investigate the antileukemic activities of recombinant interferon beta (rIFN beta) in chronic-phase CML in vitro and in vivo. Nine patients in the early chronic-phase of CML were treated in a phase-II trial with escalating doses of rIFN beta. In parallel, antiproliferative and immunomodulatory activities of rIFN beta and rIFN alpha 2b were studied in vitro. rIFN beta exhibited a significantly higher antiproliferative activity on hematopoietic progenitor cells of CML patients in vitro than rIFN alpha 2b. In contrast, only very limited clinical antileukemic efficacy of rIFN beta was observed. None of the patients achieved a complete or partial hematologic respo…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAlpha (ethology)Interferon alpha-2PharmacologyNeopterinIn vivoInternal medicineHumansMedicineBeta (finance)AgedHematologyDose-Response Relationship Drugbusiness.industryInterferon-alphaInterferon-betaHematologyGeneral MedicineImmunotherapyMiddle AgedReceptor antagonistmedicine.diseaseBiopterinRecombinant ProteinsCytokineGenesLeukemia Myeloid Chronic-PhaseImmunologyFemaleInterferonsbeta 2-MicroglobulinbusinessChronic myelogenous leukemiaAnnals of Hematology
researchProduct

Hepatitis C virus viral kinetics during α-2a or α-2b pegylated interferon plus ribavirin therapy in liver transplant recipients with different immuno…

2012

Abstract Background Predictors of sustained virological response (SVR) to antiviral therapy post-liver transplantation (LT) for chronic hepatitis C are needed. In non-transplanted patients, viral kinetics can predict SVR. Objectives To determine the early viral kinetics in LT recipients with different immunosuppression (tacrolimus – Tac- vs. cyclosporine – CsA-) during treatment with peg-IFN + RBV. Study design Prospective pilot study in HCV-1b infected patients: (LT CsA n = 8; Tac n = 8; non-LT n = 4), treated with IFN α-2a vs. α-2b (180 μg or 1.5 μg/kg, respectively) once weekly plus weight-based RBV. Median CsA or Tac baseline trough levels were 141 and 7.70 ng/mL, respectively. HCV-RNA …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentHepatitis C virusPilot ProjectsHepacivirusInterferon alpha-2Biologymedicine.disease_causeAntiviral AgentsGastroenterologyPolyethylene GlycolsImmunocompromised Hostchemistry.chemical_compoundPegylated interferonVirologyInternal medicineRibavirinmedicineHumansProspective StudiesAgedRibavirinInterferon-alphaImmunosuppressionHepatitis C ChronicMiddle AgedViral LoadViral kineticsRecombinant ProteinsTacrolimusLiver TransplantationTransplantationKineticsTreatment OutcomeInfectious DiseaseschemistryHost-Pathogen InteractionsImmunologyFemaleViral loadmedicine.drugJournal of Clinical Virology
researchProduct

Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combin…

2010

There is a lack of information on the characteristics of patients with chronic hepatitis C virus infection (HCV) who fail to respond to antiviral treatment. We studied HCV-positive subjects with chronic liver diseases treated with pegylated-interferon (PEG-IFN) and ribavirin (RBV) who failed to clear HCV in routine clinical practice. A total of 2150 consecutive adult patients treated with PEG-IFN plus RBV therapy in 46 Italian centres between 1 July 2004, and 30 June 2005, were studied. Of the 2150 patients, 923 (42.9%) (M/F 585/335, mean age 54.8 years) failed to achieve a serum HCV-RNA clearance. Of these 923 patients, 429 (46.5%) were nonresponders, 298 (32.3%) relapsers, 168 (18.2%) dro…

AdultMalenon-responders.relapserGenotypebody mass index; cirrhosis; hepatitis c virus; nonresponder; pegylated-interferon; relapserInfectious Diseasebody mass indexHepacivirusvirusInterferon alpha-2Antiviral AgentsPolyethylene GlycolPolyethylene GlycolsMedication Adherencebody mass index; cirrhosis; hepatitis C; virus; nonresponder; pegylated-interferon; relapserRisk FactorsRetrospective StudienonresponderVirologyRibavirinHumansAge FactorTreatment FailureRetrospective StudiesAgedAntiviral AgentSettore MED/12 - GastroenterologiaHCV; Antiviral therapy; Body mass index; Cirrhosis; Hepatitis C virus; Nonresponder; Pegylated-interferon; RelapserCirrhosiHepaciviruHepatologyRisk FactorcirrhosisAge FactorsInterferon-alphahepatitis c virusHepatitis C ChronicMiddle AgedRecombinant ProteinRecombinant ProteinsItalyRNA ViralFemalehepatitis Cpegylated-interferonHepatitis C viruHuman
researchProduct

Desensitization of inhibitory prejunctional alpha 2-adrenoceptors and putative imidazoline receptors on rabbit heart sympathetic nerves.

1993

To find out whether sympathetic nerves of the rabbit heart possess pharmacologically relevant prejunctional imidazoline receptors different from α-autoreceptors, the inhibition by oxymetazoline, aganodine and BDF 6143 (4-chloro-2-[2-imidazoline-2-ylamino]-isoindoline hydrochloride) of endogenous noradrenaline overflow evoked by stimulation of extrinsic postganglionic sympathetic nerves (0.66 Hz, 80 pulses) was investigated. In addition we wanted to find out whether either type of these prejunctional receptors undergoes desensitization upon pre-exposure to respective agonists. The α2-adrenoceptor agonist oxymetazoline inhibited the evoked noradrenaline overflow (2.9 nmol/l, IC50; about 90010…

Agonistmedicine.medical_specialtySympathetic Nervous Systemmedicine.drug_classReceptors DrugRauwolscineOxymetazolineImidazoline receptorStimulationMuscarinic agonistchemistry.chemical_compoundNorepinephrineReceptors Adrenergic alpha-2Internal medicinemedicinePrazosinAnimalsAdrenergic alpha-AntagonistsAutoreceptorsPharmacologyHeartGeneral MedicineEndocrinologychemistryAutoreceptorImidazoline ReceptorsRabbitsAdrenergic alpha-Agonistsmedicine.drugNaunyn-Schmiedeberg's archives of pharmacology
researchProduct

The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart

2021

Nonalcoholic fatty liver disease (NAFLD) is strongly associated to the features of metabolic syndrome which can progress to cirrhosis, liver failure and hepatocellular carcinoma. However, the most common cause of mortality in people with NAFLD is not liver-related but stems from atherosclerotic cardiovascular disease (CVD). The prevalence of NAFLD is on the rise, mainly as a consequence of its close association with two major worldwide epidemics, obesity and type 2 diabetes (T2D). The exact pathogenesis of NAFLD and especially the mechanisms leading to disease progression and CVD have not been completely elucidated. Human fetuin-A (alpha-2-Heremans Schmid glycoprotein), a glycoprotein produ…

Cirrhosisalpha-2-HS-GlycoproteinQH301-705.5030209 endocrinology & metabolismReviewType 2 diabetes030204 cardiovascular system & hematologyBioinformaticsdigestive systemCatalysisInorganic ChemistryPathogenesis03 medical and health sciences0302 clinical medicineInsulin resistanceNon-alcoholic Fatty Liver DiseaseNAFLDNonalcoholic fatty liver diseaseAnimalsHumansMedicineBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologyCVD Fetuin‐A NAFLD Animals Cardiovascular Diseases Fibrosis Humans Liver Non-alcoholic Fatty Liver Disease alpha-2-HS-GlycoproteinSpectroscopybusiness.industryOrganic Chemistrynutritional and metabolic diseasesGeneral MedicineCVDmedicine.diseaseFibrosisObesitydigestive system diseasesFetuin-AComputer Science ApplicationsChemistryLiverCardiovascular DiseasesHepatocellular carcinomaMetabolic syndromebusinessInternational Journal of Molecular Sciences
researchProduct

Preclinical evidence of new opioid modulators for the treatment of addiction.

2010

Addiction to opiates is one of the most severe forms of substance dependence, and despite a variety of pharmacological approaches to treat it, relapse is observed in a high percentage of subjects. New pharmacological compounds are necessary to improve the outcome of treatments and reduce adverse side effects. Moreover, drugs that act on the opioid system can also be of benefit in the treatment of alcohol or cocaine addiction. AREA COVERED BY THIS REVIEW: Recent preclinical studies of pharmacological agents for the treatment of opiate addiction (2008 to the present date).The reader will be informed of the latest drugs shown in animal models to modify dependence on opiates and the reinforcing…

DrugGABA Agentsmedia_common.quotation_subjectNarcotic AntagonistsDrug Evaluation PreclinicalReceptors Opioid muPharmacologyReceptors NicotinicBioinformaticsPharmacotherapyDopamineReceptors Opioid deltaCannabinoid Receptor ModulatorsmedicineAdrenergic alpha-2 Receptor AgonistsAnimalsPharmacology (medical)Adverse effectmedia_commonPharmacologySubstance dependencebusiness.industryAddictionReceptors Opioid kappaAntagonistGeneral Medicinemedicine.diseaseOpioid-Related DisordersRatsSubstance Withdrawal SyndromeOpioidReceptors OpioidDopamine AntagonistsFemalebusinessExcitatory Amino Acid Antagonistsmedicine.drugExpert opinion on investigational drugs
researchProduct

Interferon-alpha 2a increases serum concentration of hyaluronic acid and type III procollagen aminoterminal propeptide in patients with chronic hepat…

1994

Interferon-alpha (IFN-alpha) has become an important drug for the treatment of chronic viral liver diseases. However, the action of IFN-alpha remains unclear. We investigated whether human recombinant IFN-alpha modulates serum concentrations of hyaluronic acid (HA) and type III procollagen aminoterminal propeptide (P-III-NP) in 56 patients with chronic hepatitis-B under IFN-alpha therapy. IFN-alpha increased the HA serum level in 44 of 46 patients and, after cessation of treatment, HA serum levels returned to the pretherapy levels. The increase of HA serum level was higher in patients with active cirrhosis (aC) than in patients with chronic persistent hepatitis (CPH) and in patients with se…

Drugmedicine.medical_specialtyCirrhosisPhysiologymedia_common.quotation_subjectBiopsyInterferon alpha-2Viruslaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicinelawInternal medicineHyaluronic acidMedicineHumansHyaluronic AcidProtein precursor030304 developmental biologymedia_commonHepatitis Chronic0303 health sciencesbusiness.industryGastroenterologyInterferon-alphaHepatologymedicine.diseaseHepatitis BPeptide FragmentsRecombinant Proteins3. Good healthProcollagen peptidaseEndocrinologychemistry030220 oncology & carcinogenesisImmunologyChronic DiseaseRecombinant DNAbusinessProcollagenFollow-Up StudiesDigestive diseases and sciences
researchProduct

Oxidative stress inhibits IFN-α-induced antiviral gene expression by blocking the JAK–STAT pathway

2006

Abstract BACKGROUND/AIMS: Unresponsiveness to IFN-alpha is common in chronic hepatitis C. Since conditions associated with an increased oxidative stress (advanced age, steatosis, fibrosis, iron overload, and alcohol consumption) reduce the likelihood of response, we hypothesized that oxidative stress may affect the antiviral actions of IFN-alpha. METHODS: We examined in a human hepatocellular carcinoma cell line (Huh-7) the effect of hydrogen peroxide (H2O2), as a generator of oxidative stress, on the IFN-alpha signaling pathway. RESULTS: Pretreatment of Huh-7 cells with 0.5-1 mM H2O2 resulted in the suppression of the IFN-alpha-induced antiviral protein MxA and of IRF-9 mRNA expression. Th…

Gene Expression Regulation ViralMyxovirus Resistance ProteinsCarcinoma HepatocellularBlotting WesternAntiviral proteinProtein tyrosine phosphataseInterferon alpha-2Biologymedicine.disease_causechemistry.chemical_compoundGTP-Binding ProteinsCell Line TumormedicineHumansRNA NeoplasmHepatologyTyk-2Reverse Transcriptase Polymerase Chain ReactionSTATLiver NeoplasmsInterferon-alphaJAK-STAT signaling pathwayTyrosine phosphorylationHydrogen PeroxideJanus Kinase 1Flow CytometryInterferon-Stimulated Gene Factor 3 gamma SubunitRecombinant ProteinsIFN-aJAK-1Oxidative StressSTAT Transcription FactorsHydrogen peroxide; IFN-a; STAT; JAK-1; Tyk-2chemistryImmunologySTAT proteinCancer researchSignal transductionTyrosine kinaseOxidative stressSignal TransductionJournal of Hepatology
researchProduct

Genetic Variability of Hepatitis C Virus before and after Combined Therapy of Interferon plus Ribavirin

2008

We present an analysis of the selective forces acting on two hepatitis C virus genome regions previously postulated to be involved in the viral response to combined antiviral therapy. One includes the three hypervariable regions in the envelope E2 glycoprotein, and the other encompasses the PKR binding domain and the V3 domain in the NS5A region. We used a cohort of 22 non-responder patients to combined therapy (interferon alpha-2a plus ribavirin) for which samples were obtained before initiation of therapy and after 6 or/and 12 months of treatment. A range of 25-100 clones per patient, genome region and time sample were sequenced. These were used to detect general patterns of adaptation, t…

Genome evolutionHepatitis C virusEvolutionary Biology/Bioinformaticslcsh:MedicineAlpha interferonGenome ViralHepacivirusBiologyVirology/Immune EvasionInterferon alpha-2Viral Nonstructural Proteinsmedicine.disease_causeGenomeAntiviral AgentsEvolution Molecularchemistry.chemical_compoundGenetics and Genomics/Population GeneticsRibavirinmedicineHumanslcsh:ScienceNS5APhylogenyGenetics:CIENCIAS DE LA VIDA::Genética ::Otras [UNESCO]Virology/Antivirals including Modes of Action and ResistanceMultidisciplinaryEvolutionary Biology/Evolutionary and Comparative GeneticsHepatitis C virusRibavirinlcsh:RGenetic VariationInterferon-alphaVirologyComplementarity Determining RegionsHepatitis CVirology/Virus Evolution and SymbiosisRecombinant ProteinsUNESCO::CIENCIAS DE LA VIDA::Genética ::OtrasHypervariable regionchemistryViral evolutionInterferonlcsh:QGenetic variabilityHepatitis C virus; Genetic variability; Interferon; Ribavirin; Combined therapyCombined therapyResearch ArticlePLoS ONE
researchProduct

Heterogeneity of HVR-1 quasispecies is predictive of early but not sustained virological response in genotype 1b-infected patients undergoing combine…

2003

ISDR mutation pattern and HVR-1 quasispecies were analyzed in HCV genotype 1b-infected patients treated with either PEG- or STD-IFN plus ribavirin, in order to find virological correlates of therapy outcome. ISDR region analysis, performed at baseline (T0) and at 4 weeks of therapy (T1), indicated that ISDR mutation pattern was not predictive of response to treatment. Moreover, no selection of putative resistant strains in the first month of therapy was observed. Viral load was not correlated with any parameter of HVR-1 heterogeneity. Among the HVR-1 heterogeneity parameters considered, complexity was inversely correlated to viral load decline at T1. In univariate analysis, complexity, prop…

GenotypeHepacivirusInterferon alpha-2Viral Nonstructural ProteinsAntiviral AgentsPolyethylene GlycolsViral ProteinsGenetic HeterogeneityRibavirinHumansViral ProteinPhylogenyAntiviral AgentHepaciviruViral Nonstructural ProteinInterferon-alphaSequence Analysis DNAHepatitis C ChronicRecombinant ProteinViral LoadRecombinant ProteinsTreatment OutcomeLinear ModelsLinear ModelDrug Therapy CombinationSequence AlignmentHuman
researchProduct